Valneva receives initial chmp assessment of its inactivated, adjuvanted covid-19 vaccine candidate vla2001

Saint herblain (france), february 25, 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has provided an initial assessment of valneva's inactivated, adjuvanted covid-19 vaccine candidate, vla2001. valneva has received a list of questions from the chmp and is confident that it will be able to respond to these in the coming days. following the company's response, the ema will provide a timetable towards anticipated conditional approval.
VALN Ratings Summary
VALN Quant Ranking